Humacyte (HUMAW) | Stock Overview & Key Data
Humacyte Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $79.80 on August 24, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Humacyte
HUMAW
|
N/A Micro-cap | -81.82% | -81.82% | -81.82% | -81.82% | -80.00% | -80.36% | -86.25% | -99.84% | -99.67% | -99.62% | -99.62% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Adagene
ADAG
|
243.81M Micro-cap | -8.88% | -9.80% | -9.57% | 91.98% | 95.11% | 83.08% | 178.91% | -74.50% | -87.09% | -87.09% | -87.09% |
|
Orchestra BioMed
OBIO
|
242.86M Micro-cap | 0.51% | 6.72% | -12.75% | -7.67% | -7.89% | 32.69% | -55.09% | -60.58% | -49.38% | -49.38% | -49.38% |
|
Third Harmonic Bio
THRD
|
242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.40% | 56.40% | -53.82% | -70.11% | -70.11% | -70.11% | -70.11% | -70.11% |
Ownership & Short Interest
Calculate Your Humacyte Investment Returns
Long-Term Investment Performance Analysis
Humacyte stock price in Jul 2016 was $36.04, A $1,000.00 lump sum investment in Humacyte made 9 years ago would be worth approximately $0.55 today, representing a negative return of -99.94%. This translates to an annualized return (CAGR) of -53.07%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is HUMAW's 52-week high and low?
- In the last 52 weeks, Humacyte reached a high of $0.60 (on July 15, 2025) and a low of $0.02 (on June 15, 2026).
- What is the market cap and P/E ratio for HUMAW?
- Curious about Humacyte's size and valuation? Its market capitalization stands at N/A. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is N/A.
- Does HUMAW pay dividends? If so, what's the yield?
- As for dividends, Humacyte isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Humacyte's main competitors or similar companies to consider before investing?
When looking at Humacyte, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Adagene
ADAG243.81M Healthcare Biotechnology 83.08% 178.91% Orchestra BioMed
OBIO242.86M Healthcare Biotechnology 32.69% -55.09% Third Harmonic Bio
THRD242.79M Healthcare Biotechnology -53.82% -70.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Humacyte Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Humacyte's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -1,313.38%, the Debt to Equity ratio from the most recent quarter is 2,101.83, and its Gross Profit Margin stands at -1,844.75%.
- What is the recent revenue and earnings growth for HUMAW?
- Looking at Humacyte's growth, its revenue over the trailing twelve months (TTM) was $2M. Compared to the same quarter last year (YoY), quarterly revenue grew by -37.98%, and quarterly earnings saw a YoY growth of N/A.
- How much of HUMAW stock is held by insiders and institutions?
- Wondering who owns Humacyte stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.